FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval

A panel of advisors to the FDA recommended Eli Lilly’s Alzheimer’s drug donanemab. If approved, it would become the second drug of its kind to enter the U.S. market after Biogen and Eisai’s Leqembi. An approval would expand treatment options for the millions of Americans with Alzheimer’s. The FDA typically follows its advisory panels’ recommendations. Eli Lilly’s donanemab showed effectiveness in treating early-stage Alzheimer’s patients. The drug faces certain risks, including brain swelling and bleeding, which would be highlighted in the label if approved. The trial saw deaths in both the drug and placebo groups. #